ArticleJournal of neuroimmunology2010
Immune modulation by chondroitin sulfate and its degraded disaccharide product in the development of an experimental model of multiple sclerosis.
Article in Journal of neuroimmunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 44 citations in OpenAlex.
- The Heterogeneous Multiple Sclerosis Lesion: How Can We Assess and Modify a Degenerating Lesion?International journal of molecular sciences · 2023Review
- Versican promotes T helper 17 cytotoxic inflammation and impedes oligodendrocyte precursor cell remyelination.Nature communications · 2022Article
- Characterization of a Thermostable and Surfactant-Tolerant Chondroitinase B from a Marine BacteriumInternational journal of molecular sciences · 2022Article
- Regulation of Macrophage and Dendritic Cell Function by Chondroitin Sulfate in Innate to Antigen-Specific Adaptive Immunity.Frontiers in immunology · 2020Review
- Targeting the Chondroitin Sulfate Proteoglycans: Evaluating Fluorinated Glucosamines and Xylosides in Screens Pertinent to Multiple Sclerosis.ACS central science · 2019Article
- The dual role of the glycosaminoglycan chondroitin-6-sulfate in the development, progression and metastasis of cancer.The FEBS journal · 2019Review
- Promoting Axon Regeneration in Adult CNS by Targeting Liver Kinase B1.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Article
- Diverse functions of protein tyrosine phosphatase σ in the nervous and immune systems.Experimental neurology · 2018Review
- Surfen, a proteoglycan binding agent, reduces inflammation but inhibits remyelination in murine models of Multiple Sclerosis.Acta neuropathologica communications · 2018Article
- Antibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity.Scientific reports · 2017Article
- Effect of a Novel Ashwagandha-based Herbomineral Formulation on Pro-inflammatory Cytokines Expression in Mouse Splenocyte Cells: A Potential Immunomodulator.Pharmacognosy magazine · 2017Article
- Reliable and High Efficiency Extraction of Kidney Immune Cells.Journal of visualized experiments : JoVE · 2016Article
- Dysregulation in microRNA expression in peripheral blood mononuclear cells of sepsis patients is associated with immunopathology.Cytokine · 2015Article
- Extracellular matrix regulation of inflammation in the healthy and injured spinal cord.Experimental neurology · 2014Review
- Inhibitors of myelination: ECM changes, CSPGs and PTPs.Experimental neurology · 2014Article
- Elastin-derived peptides are new regulators of insulin resistance development in mice.Diabetes · 2013Article
- Indoles mitigate the development of experimental autoimmune encephalomyelitis by induction of reciprocal differentiation of regulatory T cells and Th17 cells.British journal of pharmacology · 2013Article
- The role of IL-2 in the activation and expansion of regulatory T-cells and the development of experimental autoimmune encephalomyelitis.Immunobiology · 2013Article
- CSPG is a secreted factor that stimulates neural stem cell survival possibly by enhanced EGFR signaling.PloS one · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Clinical symptoms in MOG-induced EAE mice significantly exacerbated following chondroitin sulfate A (CS-A) injection, whereas administration of a degraded product, CSPG-DS, caused dramatic inhibition of EAE development. Also, administration of CSPG-DS but not CS-A, after the onset of clinical symptoms of EAE, was able to suppress the disease. Further studies demonstrated that CS-A up-regulated STAT4 expression and thus, induced IFN-gamma production and Th1 CD4 T cell differentiation. CS-A also up-regulated STAT3 and IL-23 expression and thus increased IL-17 producing T cells. CSPG-DS treatment both in vivo and in vitro decreased TNFalpha production from splenocytes. In vitro and in vivo studies indicated that CSPG-DS treatment in EAE mice significantly blocked migration of lymphocytes, whereas CS-A treatment increased lymphocyte infiltration in the brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.